US 12,433,885 B2
Procaspase combination therapy for glioblastoma
Paul J. Hergenrother, Champaign, IL (US); Rachel C Botham, Champaign, IL (US); Timothy M. Fan, Mahomet, IL (US); Mark J. Gilbert, Seattle, WA (US); Michael K. Handley, Windsor, CO (US); Avadhut Joshi, Towson, MD (US); Gregory J. Riggins, White Hall, MD (US); and Theodore M. Tarasow, San Ramon, CA (US)
Assigned to THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US); VANQUISH ONCOLOGY, INC., Champaign, IL (US); and THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US)
Filed by THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, Urbana, IL (US); VANQUISH ONCOLOGY, INC., Champaign, IL (US); and THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US)
Filed on Nov. 21, 2023, as Appl. No. 18/516,174.
Application 18/516,174 is a continuation of application No. 17/130,387, filed on Dec. 22, 2020, granted, now 11,844,798.
Application 17/130,387 is a continuation of application No. 16/148,344, filed on Oct. 1, 2018, granted, now 10,874,666, issued on Dec. 29, 2020.
Application 16/148,344 is a continuation of application No. 15/243,860, filed on Aug. 22, 2016, granted, now 10,085,978, issued on Oct. 2, 2018.
Application 15/243,860 is a continuation of application No. 14/383,460, granted, now 9,421,202, issued on Aug. 23, 2016, previously published as PCT/US2013/029391, filed on Mar. 6, 2013.
Claims priority of provisional application 61/607,103, filed on Mar. 6, 2012.
Prior Publication US 2024/0082241 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/495 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/4188 (2006.01); A61K 31/53 (2006.01); A61K 47/10 (2017.01)
CPC A61K 31/495 (2013.01) [A61K 9/0019 (2013.01); A61K 9/008 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/4858 (2013.01); A61K 31/4188 (2013.01); A61K 31/53 (2013.01); A61K 47/10 (2013.01)] 16 Claims
 
1. A method of treating a brain cancer in a human subject in need thereof comprising administering to a human subject, concurrently or sequentially, a therapeutically effective amount of each of the compounds temozolomide (TMZ) and first procaspase activating compound (PAC-1):

OG Complex Work Unit Chemistry
wherein the therapeutically effective amount of each of the compounds TMZ and PAC-1 is about 8.1 mg/kg, or about 300 mg/m2, wherein the TMZ and PAC-1 form a synergistic anticancer combination that is about 56% to about 316% more effective than an additive anticancer effect of TMZ and PAC-1, the brain cancer is glioblastoma multiform or meningioma, and the glioblastoma multiform or meningioma is thereby treated.